BioMarin Pharmaceutical (BMRN) Leerink Global Healthcare Conference 2026 summary

Strategic growth and financial outlook

• Achieved 13% total revenue growth in 2025, with Skeletal Conditions up 26% and Enzyme Therapies up 9%.

• Guidance for 2026 projects high single-digit growth in both business units.

• Amicus acquisition expected to close in Q2, adding two high-growth rare disease products.

• Focus on efficient cost allocation and disciplined expense management has led to leveraged earnings growth and margin expansion.

• Transaction with Amicus may be slightly dilutive in 2026 but is expected to be accretive within 12 months and substantially accretive thereafter.

Pipeline and innovation milestones

• Recent approval of PALYNZIQ in adolescents and two phase III data readouts expected in 2026: VOXZOGO for hypochondroplasia and BMN 401 for ENPP1 deficiency.

• Advancing clinical-stage assets including BMN 351 for Duchenne muscular dystrophy and BMN 333, a long-acting CNP for achondroplasia.

• BMN 333 phase II/III trial aims to demonstrate superiority over VOXZOGO in growth and health benefits.

• BMN 351 program targets 10% dystrophin expression, with next data from higher dose cohorts and focus on clinical benefit correlation.

• ENERGY 3 phase III data for ENPP1 deficiency expected in first half of 2026, with a global addressable population estimated at 2,000–2,500.

Commercial execution and market dynamics

• VOXZOGO revenues are expected to be higher in the second half of 2026 due to international order timing, with 75% of revenue from outside the U.S.

• Market research indicates low likelihood of switching therapies if efficacy and safety are established, with convenience as a secondary factor.

• Ongoing efforts to expand disease awareness and diagnosis for hypochondroplasia and ENPP1 deficiency to maximize patient reach.

• Long-term data and publications support VOXZOGO’s benefits beyond height, including proportionality and quality of life improvements.

• Amicus products Galafold and Pompe expected to benefit from broader country footprint and deeper market penetration, with a focus on diagnosis and real-world evidence generation.